Clindamycin hydrochloride - Generic Drug Details

What are the generic drug sources for clindamycin hydrochloride and what is the scope of freedom to operate?

Clindamycin hydrochloride is the generic ingredient in three branded drugs marketed by Pharmacia And Upjohn, Pfizer, Aurobindo Pharma, Chartwell Molecular, Cosette, Epic Pharma Llc, Glenmark Pharms Ltd, Micro Labs, Pharmobedient, Sun Pharm Inds Ltd, Teva, Watson Labs, and Zydus Pharms Usa, and is included in fourteen NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty drug master file entries for clindamycin hydrochloride. Thirty-four suppliers are listed for this compound.

Summary for clindamycin hydrochloride

US Patents:	0
Tradenames:	3
Applicants:	13
NDAs:	14
Drug Master File Entries:	20
Finished Product Suppliers / Packagers:	34
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	251
Patent Applications:	2,388
What excipients (inactive ingredients) are in clindamycin hydrochloride?	clindamycin hydrochloride excipients list
DailyMed Link:	clindamycin hydrochloride at DailyMed

Recent Clinical Trials for clindamycin hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Assistance Publique - Hpitaux de Paris	PHASE2
McGill University Health Centre/Research Institute of the McGill University Health Centre	PHASE4
Nantes University Hospital	PHASE2

See all clindamycin hydrochloride clinical trials

Pharmacology for clindamycin hydrochloride

Drug Class	Lincosamide Antibacterial
Physiological Effect	Decreased Sebaceous Gland Activity Neuromuscular Blockade

Anatomical Therapeutic Chemical (ATC) Classes for clindamycin hydrochloride

D10AF	Antiinfectives for treatment of acne
D10A	ANTI-ACNE PREPARATIONS FOR TOPICAL USE
D10	ANTI-ACNE PREPARATIONS
D	Dermatologicals

G01AA	Antibiotics
G01A	ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS
G01	GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS
G	Genito-urinary system and sex hormones

J01FF	Lincosamides
J01F	MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for clindamycin hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmobedient	CLINDAMYCIN HYDROCHLORIDE	clindamycin hydrochloride	CAPSULE;ORAL	091225-001	May 31, 2011		DISCN	No	No
Glenmark Pharms Ltd	CLINDAMYCIN HYDROCHLORIDE	clindamycin hydrochloride	CAPSULE;ORAL	216957-003	Mar 10, 2023	AB	RX	No	No
Chartwell Molecular	CLINDAMYCIN HYDROCHLORIDE	clindamycin hydrochloride	CAPSULE;ORAL	065243-002	Aug 12, 2005	AB	RX	No	No
Pharmacia And Upjohn	CLEOCIN	clindamycin hydrochloride	CAPSULE;ORAL	061809-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Watson Labs	CLINDAMYCIN HYDROCHLORIDE	clindamycin hydrochloride	CAPSULE;ORAL	063082-001	Jul 31, 1991		DISCN	No	No

Clindamycin hydrochloride Market Analysis and Financial Projection

Last updated: February 12, 2026

What Are the Current Market Dynamics for Clindamycin Hydrochloride?

The global market for clindamycin hydrochloride, an antibiotic used to treat bacterial infections, experienced steady growth over recent years. Key drivers include rising antibiotic prescriptions, increasing bacterial resistance, and expanded clinical indications. The drug is marketed primarily in oral, injectable, and topical formulations.

Market Size and Growth

• The global antibiotic market was valued at approximately $52 billion in 2021, with clindamycin hydrochloride accounting for a significant share due to its widespread use.
• The compound's market is projected to grow at a compound annual growth rate (CAGR) of 3.5% between 2022 and 2028. This expansion results from increased prevalence of bacterial infections and initiatives to combat antimicrobial resistance.

Regional Market Distribution

• North America, especially the U.S., dominates the market, driven by high healthcare expenditure, prescription rates, and antibiotic resistance concerns.
• Europe follows, with growth supported by aging populations and rising bacterial infection rates.
• Asia-Pacific exhibits high growth potential due to increased healthcare infrastructure investment and antibiotic consumption, projected to grow at a CAGR of 4.8%.

Competitive Landscape

• Major pharmaceutical companies such as Pfizer, Lupin, Mofe Pharma, and Sandoz manufacture generic versions of clindamycin hydrochloride.
• Patent expirations for branded formulations have increased generic competition, lowering prices and expanding access.
• Manufacturers focus on formulation improvements, including extended-release tablets and topical gel variants, to differentiate products.

Key Market Challenges

• Antibiotic resistance hampers efficacy, leading to stricter prescribing guidelines.
• Side-effect profiles, including gastrointestinal disturbances, influence prescribing practices.
• Regulatory scrutiny around antibiotic use encourages optimization of dosing regimens and stewardship programs.

How Does the Financial Trajectory Look for Clindamycin Hydrochloride?

Revenue Trends and Forecasts

• The global revenue from clindamycin hydrochloride drugs is estimated at approximately $1.2 billion for 2022.
• Revenue growth is expected to sustain at a CAGR of 3.2% through 2028, driven by increased adoption and expanding indications.

Price Trends

• Generic competition has driven prices downward. The average wholesale price (AWP) for oral clindamycin hydrochloride has decreased by approximately 20% over the past three years.
• Price erosion impacts profit margins but increases accessibility, facilitating broader use.

Research and Development Investment

• Companies invest in formulations with enhanced safety profiles and convenience, such as topical gels and long-acting injectables.
• R&D budgets allocated to antibiotic development average around 5-8% of sales in companies active in this space.

Regulatory and Policy Impact

• Recent FDA initiatives promote antibiotic stewardship and outline stricter approval pathways for new antibacterial agents.
• Local regulatory variations influence market entry timelines and pricing strategies.

M&A and Licensing Trends

• Mergers and acquisitions focus on consolidating generic portfolios. For instance, in 2021, Teva Pharmaceuticals acquired a portfolio of generic antibiotics, including clindamycin formulations.
• Licensing deals facilitate regional distribution rights, especially in emerging markets.

What Are the Key Factors Influencing Future Market and Financial Outcomes?

• Antibiotic Resistance: Rising resistance levels may lead to reduced use of clindamycin, replaced by newer agents.
• Regulatory Changes: Stringent guidelines could affect prescribing patterns, impacting sales volumes.
• Innovation in Formulations: Development of narrow-spectrum, targeted delivery systems can sustain demand.
• Pandemic Impact: Increased bacterial infection rates during health crises can temporarily boost sales.

Summary of Market and Financial Data

Aspect	2022 Data	Future Outlook (2023-2028)
Global Market Value	$1.2 billion	CAGR of 3.2%
Regional Growth (Asia-Pacific)	5% growth rate	Highest growth among regions
Price Trends	20% price decrease in oral formulations	Prices expected to stabilize at lower levels
R&D Investment	5-8% of sales	Focus on safe, convenient formulations
Patent Status	Patent expirations in 2019-2022	Increased generic competition

Key Takeaways

• The clindamycin hydrochloride market remains stable with moderate growth driven by global bacterial infection rates.
• Generic competition and price erosion challenge profitability but expand access.
• Regulatory pressures and antibiotic resistance are key risks.
• Innovation in formulations and strategic M&A influence future financial trajectories.
• Emerging markets offer significant growth opportunities due to increasing healthcare investments.

FAQs

1. How is antibiotic resistance impacting the clindamycin hydrochloride market?
Growth in bacterial resistance reduces the drug’s efficacy, prompting clinicians to reserve its use and turn to newer antibiotics—potentially decreasing future sales.

2. What are the main formulations of clindamycin hydrochloride available?
It is available as oral capsules, injectable solutions, topical gels, and clindamycin phosphate combinations.

3. Which regions are driving future demand?
The Asia-Pacific region is projected to experience the highest CAGR due to rising healthcare infrastructure and antibiotic consumption.

4. How do patent expirations influence the market?
Patent expirations increase generic competition, lowering prices and expanding access but reducing profit margins for originators.

5. What innovations are shaping the future of clindamycin hydrochloride?
Focus areas include topical gel formulations with improved safety, extended-release tablets, and targeted delivery systems.

---

Sources

1. Grand View Research. Antibiotics Market Analysis, 2022.
2. EvaluatePharma. 2022 Pharmaceutical Market Data.
3. FDA. Antibacterial Drugs Guidance, 2020.
4. IQVIA. Global Prescription Antibiotic Sales Report, 2022.
5. Mergent. Company M&A Reports, 2021.